Patent application number | Description | Published |
20090221006 | DIAGNOSIS, PREVENTION AND TREATMENT OF CROHN'S DISEASE USING THE OMPC ANTIGEN - The present invention provides a method of diagnosing Crohn's disease in a subject by determining the presence or absence or IgA anti-OmpC antibodies in the subject, where the presence of the IgA anti-OmpC antibodies indicates that the subject has Crohn's disease. | 09-03-2009 |
20090221007 | DIAGNOSIS, PREVENTION AND TREATMENT OF CROHN'S DISEASE USING THE OMPC ANTIGEN - The present invention provides a method of diagnosing Crohn's disease in a subject by determining the presence or absence or IgA anti-OmpC antibodies in the subject, where the presence of the IgA anti-OmpC antibodies indicates that the subject has Crohn's disease. | 09-03-2009 |
20100196509 | Methods for Diagnosis and Treatment of Endometrial Cancer - The present invention discloses methods of using endothelial membrane protein 2 (EMP2) as a biomarker for stratification of endometrial premalignancy, diagnosing, staging and imaging of endometrial neoplasia. Further, methods for identifying pharmaceutical/therapeutic modalities are described, including compositions which modulate glycolipid-enriched lipid raft microdomains (GEMs). | 08-05-2010 |
20100267037 | GENOTOXICITY AS A BIOMARKER FOR INFLAMMATION - The invention provides a method for detection of inflammatory disease in a subject that comprises assaying a test sample of peripheral blood from the subject for a marker of DNA damage. An elevated amount of marker present in the test sample compared to control sample is indicative of inflammatory disease activity, including sub-clinical inflammation. The method can be adapted for quantitatively monitoring the efficacy of treatment of inflammatory disease in a subject. Markers of DNA damage include single- and/or double-stranded breaks in leukocytes, oxidative DNA damage in leukocytes, or a marker of nitric oxide oxidative activity (protein nitrosylation in leukocytes). The inflammatory disease can be inflammatory bowel disease (ulcerative colitis or Crohn's disease). The invention may also be used for detection of other types of inflammatory disease, such as non-immune intestinal inflammatory disease (diverticulitis, pseudomembranous colitis), autoimmune diseases (rheumatoid arthritis, lupus, multiple sclerosis, psoriasis, uveitis, vasculitis), or non-immune lung diseases (asthma, chronic obstructive lung disease, and interstitial pneumonitis). This unexpected discovery of markers of genotoxicity present in circulating leukocytes enables detection of inflammation occurring at a localized site with a relatively simple and minimally invasive assay using peripheral blood. | 10-21-2010 |
20100272732 | EMP2 ANTIBODIES AND THEIR THERAPEUTIC USES - The present invention provides methods and compositions useful in the treatment or prevention of | 10-28-2010 |
20110124644 | METHODS OF DIAGNOSING AND CHARACTERIZING CANNABINOID SIGNALING IN CROHN'S DISEASE - Diagnosis of Crohn's Disease by determining the presence or absence of variants at the CNR2 (cannabinoid) genetic locus and serological markers is disclosed Methods of diagnosing a Crohn's Disease sub-type by determining the presence or absence of one or more risk variants at the CNR2 5 locus and the presence or absence of ASCA, OmpC, 12 and/or anti-Cbir1 antibodies are included | 05-26-2011 |
20120020983 | EMP2 ANTIBODIES AND THEIR THERAPEUTIC USES - The present invention provides methods and compositions useful in the treatment or prevention of | 01-26-2012 |
20120264620 | METHODS FOR DIAGNOSIS AND TREATMENT OF ENDOMETRIAL CANCER - The present invention discloses methods of using endothelial membrane protein 2 (EMP2) as a biomarker for stratification of endometrial premalignancy, diagnosing, staging and imaging of endometrial neoplasia. Further, methods for identifying pharmaceutical/therapeutic modalities are described, including compositions which modulate glycolipid-enriched lipid raft microdomains (GEMs). | 10-18-2012 |
20130034555 | EPITHELIAL MEMBRANE PROTEIN 2 (EMP2) BINDING REAGENTS AND THEIR THERAPEUTIC USES IN OCULAR DISEASES - A method is disclosed for treating diseases or disorders of the eye involving undesired expression of vascular endothelial growth factor (VEGF) by administration of endothelial membrane protein 2 (EMP2) inhibitor. The present invention relates to the direct treatment of macular degeneration, particularly age-related macular degeneration (AMD), by administering an EMP2 inhibitor intraocularly or systemically. | 02-07-2013 |
20130230527 | EMP2 ANTIBODIES AND THEIR THERAPEUTIC USES - The present invention provides methods and compositions useful in the treatment or prevention of | 09-05-2013 |
20130323746 | GENOTOXICITY AS A BIOMARKER FOR INFLAMMATION - The invention provides a method for detection of inflammatory disease in a subject that comprises assaying a test sample of peripheral blood from the subject for a marker of DNA damage. An elevated amount of marker present in the test sample compared to control sample is indicative of inflammatory disease activity, including sub-clinical inflammation. The method can be adapted for quantitatively monitoring the efficacy of treatment of inflammatory disease in a subject. Markers of DNA damage include single- and/or double-stranded breaks in leukocytes, oxidative DNA damage in leukocytes, or a marker of nitric oxide oxidative activity (protein nitrosylation in leukocytes). The inflammatory disease can be inflammatory bowel disease (ulcerative colitis or Crohn's disease). The invention may also be used for detection of other types of inflammatory disease, such as non-immune intestinal inflammatory disease (diverticulitis, pseudomembranous colitis), autoimmune diseases (rheumatoid arthritis, lupus, multiple sclerosis, psoriasis, uveitis, vasculitis), or non-immune lung diseases (asthma, chronic obstructive lung disease, and interstitial pneumonitis). This unexpected discovery of markers of genotoxicity present in circulating leukocytes enables detection of inflammation occurring at a localized site with a relatively simple and minimally invasive assay using peripheral blood. | 12-05-2013 |
20130344078 | EMP2 ANTIBODIES AND THEIR THERAPEUTIC USES - The present invention provides methods and compositions useful in the treatment or prevention of | 12-26-2013 |
20140072569 | EMP2 ANTIBODIES AND THEIR THERAPEUTIC USES - The present invention provides methods and compositions useful in the treatment or prevention of | 03-13-2014 |
20140234308 | TREATMENT OF BREAST CANCER WITH COMPANION DIAGNOSTIC - Despite advances in therapy, breast cancer remains the most common malignancy in women. Of particular concern is the aggressive triple negative subtype that lacks the BRCA1 mutation, estrogen receptor, and epidermal growth factor type 2 receptor (Her-2/neu), which accounts for approximately half of all breast cancer deaths. Provided herein are compositions and methods for treating breast cancer, including the triple negative subtype. | 08-21-2014 |
20150079089 | EMP2 REGULATES ANGIOGENESIS IN CANCER CELLS THROUGH INDUCTION OF VEGF - Disclosed herein are methods and compositions for modulating neovascularization. The disclosed compositions find particular use in the treatment of uterine cancers, specifically endometrial cancers. | 03-19-2015 |
20150079116 | DIAGNOSTIC TOOLS FOR RESPONSE TO 6-THIOPURINE THERAPY - NK cell licensing predisposes patients to chronic inflammatory disease. Methods and kits to diagnose and treat chronic inflammatory disease based on genetic haplotype and cytokine profile are described herein. | 03-19-2015 |